
Opinion|Videos|May 21, 2025
Place of Continuous Subcutaneous Infusion Systems in Parkinson Disease Management
Panelists discuss how continuous subcutaneous infusion systems should be strategically positioned within Parkinson disease management, typically as options for patients with advanced disease experiencing motor fluctuations despite optimized oral therapy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Placement of Infusion Therapies in Parkinson Disease Management
- Consider after oral medication optimization fails to provide adequate control
- Position before deep brain stimulation (DBS) in treatment algorithm
- Appropriate for patients with medication-responsive symptoms but problematic motor fluctuations
- Viable option when cognitive/psychiatric issues contraindicate DBS
- Can be used as a transitional therapy before considering more invasive options
- Particularly valuable for patients with unpredictable off periods
- May be considered earlier in disease course than traditionally recommended for advanced therapies
- Best implemented with a multidisciplinary team approach (neurology, nursing, pharmacy)
- Should be part of a comprehensive care plan addressing motor and nonmotor symptoms
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission
2
GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease
3
Understanding the Barriers of Health Insurance in Stroke Rehabilitation Care
4
Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine
5




































